Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors

Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site Binding of Arylpiperazines, (Aryloxy)propanolamines, and Tetrahydropyridylindoles to the 5-HT_1A Receptor:  Contribution of the Molecular Lipophilicity Potential to Three-Dimensional Quantitative Structure−Affinity Relationship Models Novel, Potent, and Selective 5-HT3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies 3D-QSAR studies of 2,2-diphenylpropionates to aid discovery of novel potent muscarinic antagonists Quantitative Analysis of the Structural Requirements for Blockade of the N-Methyl-<scp>d</scp>-aspartate Receptor at the Phencyclidine Binding Site Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to α1-adrenergic receptors among arylpiperazine derivatives of phenytoin Novel Potent and Selective Central 5-HT₃ Receptor Ligands Provided with Different Intrinsic Efficacy. 1. Mapping the Central 5-HT₃ Receptor Binding Site by Arylpiperazine Derivatives Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A₁Receptor Antagonists